Psoriatic Arthritis
Exploring Psoriatic Arthritis: Bridging
Dermatology and Rheumatology
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: July 2, 2009
Expiration Date: July 2, 2010
Estimated Time of Completion: 1 hour 15 minutes
Description
Presented through an expert panel discussion, this activity is intended to explore strategies for managing patients with psoriatic arthritis from both dermatology and rheumatology perspectives, focusing on challenges related to the recognition, assessment, diagnosis, and treatment of cutaneous and musculoskeletal disease in these patients.
Objectives
On completion of this activity, participants should be able to:
- Outline the cutaneous and musculoskeletal features of psoriatic arthritis.
- Describe available classification criteria and methodology to assist in making a diagnosis of psoriatic arthritis.
- Discuss the impact of psoriatic arthritis on quality of life and morbidity.
- Select systemic therapies for psoriatic arthritis considering varying severity. of cutaneous and musculoskeletal manifestations; monitor these therapies for safety and efficacy.
- Compare and contrast treatment approaches for cutaneous and musculoskeletal manifestations of psoriatic arthritis.
- Describe the beneficial aspects of optimizing interdisciplinary exchanges in the care of the patient with psoriatic arthritis.
Target Audience
This activity is targeted to physicians who treat patients for psoriatic arthritis such as dermatologists or rheumatologists, or other practitioners who also treat patients for psoriatic arthritis such as dermatology and rheumatology physician’s assistants or nurse practitioners.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
This program has been reviewed and is approved for a maximum of 1.0 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for 1 year from the issue date of July 1, 2009. Participants may submit the self-assessment at any time during that period. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program is approved for 1.0 contact hour(s) of continuing education by the American Academy of Nurse Practitioners. Program ID 0906238. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Credit certificates for Nurse Practitioners and Physician Assistants will be mailed out within 6 weeks after activity completion. If you have questions regarding your AAPA Category 1 CME credit or AANP contact hours, please contact DIME at 312.553.8000.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
PsA Steering Committee Members
| M. Elaine Husni, MD, MHP Assistant Professor Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Vice Chair of Rheumatology and Director Arthritis and Musculoskeletal Center Staff Physician Orthopedic and Rheumatologic Institute Cleveland Clinic Cleveland, Ohio |
Mark Lebwohl, MD Professor and Chairman Department of Dermatology The Mount Sinai School of Medicine New York, New York |
| Philip Mease, MD Chief of Rheumatology Research Swedish Medical Center Clinical Professor of Medicine University of Washington Seattle, Washington |
Abrar Qureshi, MD, MPH Assistant Professor of Dermatology Brigham and Women’s Hospital Harvard Medical School Boston, Massachusetts |
| Melodie Young, RN, MSN, ANP-C, GNP-C Adjunct Clinical Instructor The University of Texas at Arlington Modern Dermatology Baylor Health Care System Dallas, Texas |
|
Faculty
| Mark Lebwohl, MD Professor and Chairman Department of Dermatology The Mount Sinai School of Medicine New York, New York |
Philip Mease, MD Chief of Rheumatology Research Swedish Medical Center Clinical Professor of Medicine University of Washington Seattle, Washington |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO | ||
| Consulting: | Abbott Laboratories; Amgen, Inc.; Centocor, Inc.; Elan Pharmaceuticals, Inc.; Genentech, Inc.; Roche Laboratories, Inc. | |
| Teaching and Speaking: | Genentech, Inc.; Amgen, Inc. | |
| Research: | Centocor, Inc. | |
| Mark Lebwohl, MD | ||
| Consulting: | Abbott Laboratories; Actelion Clinical Research; Amgen and Wyeth Pharmaceuticals; Astellas Pharma US; Centocor, Inc.; Cerexa, Inc.; DermiPsor LTD; Electro-Optical Sciences, Inc.; Galderma S.A.; Genentech, Inc.; HelixBioMedix, Inc.; Magen Biosciences, Inc.; Medicis Pharmaceutical Corporation; NeoStrata Company; Novartis; Nycomed; Peplin Inc.; Ranbaxy Laboratories; sanofi-aventis Group; Stiefel Laboratories, Inc.; Taro Pharmaceutical Industries Ltd; Triax Pharmaceuticals; Warner Chilcott; York Pharma Plc | |
| Philip Mease, MD | ||
| Consulting: | Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Centocor, Inc.; Genentech, Inc.: Pfizer Inc; Roche; sanofi-aventis Group; UCB; Wyeth Pharmaceuticals | |
| Independent Contractor: | Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Centocor, Inc.; Genentech, Inc.: Pfizer Inc; Wyeth Pharmaceuticals | |
| Teaching and Speaking: | Abbott Laboratories; Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Centocor, Inc.; Genentech, Inc.: Pfizer Inc; Wyeth Pharmaceuticals | |
| Melodie Young, RN, MSN, ANP-C, GNP-C | ||
| Consulting: | Abbott Laboratories; Amgen Inc.; Astellas Pharma US, Inc.; Centocor, Inc.; and Genentech, Inc. | |
| Teaching and Speaking: | Abbott Laboratories; Amgen Inc.; Astellas Pharma US, Inc.; Centocor, Inc.; and Genentech, Inc. | |
| Membership on advisory committee or review panels: | Abbott Laboratories; Amgen Inc.; Astellas Pharma US, Inc.; Centocor, Inc.; and Genentech, Inc. | |
The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Elaine Husni, MD, MPH
Abrar Qureshi, MD, MPH
This program is supported by the National Psoriasis Foundation as an Approved Education Partnership as it helps to improve the quality of life for people with psoriasis and psoriatic arthritis. The Psoriasis Foundation is a nonprofit organization that does not recommend or endorse any specific treatment or product for psoriasis or psoriatic arthritis. This program was reviewed, but not developed by the Foundation.
This activity is supported by an educational donation provided by Amgen.
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME .
